Insights
Search Results
Client Highlights
3.31.26
Wilson Sonsini Advises Helix Earth on $12 Million Seed 2 Funding
On March 26, 2026, Helix Earth, a hardware company built on proprietary liquid-gas chemistry with roots in NASA aerospace technology, announced the successful close of its $12 million oversubscribed Seed 2 funding. The oversubscribed financing round was led by Veriten, with participation from Rua Ventures, Carnrite Ventures, Skywriter LLC, Textbook Ventures, and others. Wilson Sonsini Goodrich & Rosati advised Helix Earth on the transaction and WS Investments participated in the round.
Client Highlights
9.25.25
Wilson Sonsini Advises LALO Tequila on Acquisition by Tito’s
On September 23, 2025, Tito's Handmade Vodka, the brand behind Texas' first legal distillery and the award-winning vodka, announced it has entered into a definitive agreement to acquire the majority stake in LALO Tequila, one of the fastest-growing tequila brands in the United States. Wilson Sonsini Goodrich & Rosati advised LALO on the transaction.
Client Highlights
9.15.25
Wilson Sonsini Advises GreenLite on $49.5 Million Series B
On September 15, 2025, GreenLite, a construction technology company accelerating permit timelines through AI-powered plan review and compliance solutions, announced a $49.5 million dollar Series B funding round, led by global software investor Insight Partners with participation from Energize Capital, as well as existing investors Craft Ventures, LiveOak Ventures, and Chicago Ventures. Wilson Sonsini Goodrich & Rosati advised GreenLite on the transaction.
Client Highlights
7.25.25
Wilson Sonsini Advises Revival on Strategic Partnership with Olympus
On July 25, 2025, Revival Healthcare Capital (Revival), an investment firm focused on transformative external innovation partnerships in MedTech, announced a strategic partnership with Olympus Corporation (Olympus), a global healthcare leader committed to making people’s lives healthier, safer, and more fulfilling through advanced medical technologies and solutions. The partnership is aimed at harnessing external innovation to accelerate development and market entry for an endoluminal robotics platform initially targeting gastrointestinal (GI) treatments. Wilson Sonsini Goodrich & Rosati advised Revival on the transaction and on fund matters related to the transaction.
Client Highlights
7.10.25
Wilson Sonsini Represents Tenstorrent in Acquisition of Blue Cheetah
On July 1, 2025, Tenstorrent, a next-generation computing company building computers for AI, announced that it had acquired Blue Cheetah Analog Design, a startup specializing in highly customized analog mixed-signal IP. Wilson Sonsini Goodrich & Rosati advised Tenstorrent on the transaction.
Client Highlights
5.13.25
Wilson Sonsini Advises QbDVision on $13 Million Strategic Investment
On May 1, 2025, QbDVision, an Austin, Texas-based digital chemistry, manufacturing, and controls (CMC) platform purpose-built for biopharma organizations, announced a $13 million strategic investment round led by prior investors Northpond Ventures and S3 Ventures, along with Create Health Ventures and company insiders. Wilson Sonsini Goodrich & Rosati advised QbDVision on the transaction.
Client Highlights
1.14.25
Wilson Sonsini Advises Alleviant Medical on $90 Million Financing
On January 14, 2025, Alleviant Medical, Inc., a privately held medical device company developing a no-implant atrial shunt for heart failure, announced a $90 million financing to fund its second pivotal trial. Led by Glide Healthcare, the round also adds Omega Funds and includes participation from existing shareholders S3 Ventures, RiverVest Venture Partners, Vensana Capital, Longview Ventures, Gilmartin Capital, TMC Venture Fund, and undisclosed strategic investors. Wilson Sonsini Goodrich & Rosati advised Alleviant on the transaction.
The new pivotal trial, ALLAY-HFrEF, will be the first prospective sham-controlled trial focused on patients with heart failure and reduced ejection fraction (HFrEF) in the atrial shunt space. Alleviant will be the only atrial shunt company to have ongoing clinical trials for the full spectrum of heart failure. The company’s first pivotal trial (ALLAY-HF), evaluating the Alleviant System’s safety and efficacy in patients with heart failure and preserved ejection fraction (HFpEF), is on track to finalize enrollment within the next year. The new trial will expand investigation to patients with the other primary form of heart failure, those with reduced ejection fraction (HFrEF).
The Wilson Sonsini team advising Alleviant on the financing was led by Rob Suffoletta and included Nathan Robinson, Alex Dolphin, and Tanner Kuenneth.
For more information, please see Alleviant’s news release.
The new pivotal trial, ALLAY-HFrEF, will be the first prospective sham-controlled trial focused on patients with heart failure and reduced ejection fraction (HFrEF) in the atrial shunt space. Alleviant will be the only atrial shunt company to have ongoing clinical trials for the full spectrum of heart failure. The company’s first pivotal trial (ALLAY-HF), evaluating the Alleviant System’s safety and efficacy in patients with heart failure and preserved ejection fraction (HFpEF), is on track to finalize enrollment within the next year. The new trial will expand investigation to patients with the other primary form of heart failure, those with reduced ejection fraction (HFrEF).
The Wilson Sonsini team advising Alleviant on the financing was led by Rob Suffoletta and included Nathan Robinson, Alex Dolphin, and Tanner Kuenneth.
For more information, please see Alleviant’s news release.
Client Highlights
12.04.24
Wilson Sonsini Advises Tenstorrent on $693 Million Series D Financing
On December 2, 2024, Tenstorrent, a next-generation computing company that builds computers for AI, announced the closing of over $693 million in its Series D funding round, at a pre-money valuation of $2 billion. Samsung Securities and AFW Partners led the round, with participation from XTX Markets, Corner Capital, MESH, Export Development Canada, Healthcare of Ontario Pension Plan, LG Electronics, Hyundai Motor Group, Fidelity Management & Research Company, Baillie Gifford, Bezos Expeditions, and more. Wilson Sonsini Goodrich & Rosati advised Tenstorrent on the transaction.
Client Highlights
7.12.24
Wilson Sonsini Advises Seismos on $15 Million Growth Investment Led by Edison Partners
On July 10, 2024, Seismos, Inc., a leader in AI-powered Acoustic Sensing, and growth equity firm Edison Partners announced a $15 million growth investment to enable and accelerate the energy industry’s shift from analog-focused exploration and production to technology-driven, digital infrastructure, and autonomous production operations. Wilson Sonsini Goodrich & Rosati advised Seismos on the transaction.
Client Highlights
4.05.24
Wilson Sonsini Advises BurnBot on $20 Million Series A Financing
On April 2, 2024, BurnBot, a tech forward provider of wildfire mitigation, vegetation management, and prescribed fire operations, announced it has raised $20 million in financing to expand its mechanized vegetation management and fuel treatment solutions to prevent destructive wildfires. The round was led by ReGen Ventures, with participation from Toyota Ventures, AmFam Ventures, Convective Capital, Blue Forest Asset Management, Skip Capital, Overture Ventures, Lowercarbon Capital, and Pathbreaker Ventures. Wilson Sonsini Goodrich & Rosati advised BurnBot on the transaction.